Tomaralimab

DB15415Investigational

Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).

Mechanism: Pharmacologically active on Toll-like receptor 2
Curator reviewed
Also known as: anti-Tlr2 monoclonal antibody OPN-305 · Humanized IGG4 monoclonal antibody against toll-like receptor 2 for prevention of ischemia/reperfusion tissue injury
Code names: NM-101 · OPN-305

Resolves to

Compound

UNIIP45C2W27DUCAS1449294-76-1

Targets

O60603TLR2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tomaralimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account